Initial Goal of Collaboration is to Develop FoundationOne®Liquid CDx as a Companion Diagnostic for Bavdegalutamide (ARV-110), Arvinas’ Investigational Androgen Receptor-Targeting PROTAC® Protein DegraderCAMBRIDGE, Mass. (BUSINESS WIRE) #ASCO22 Today Foundation Medicine, Inc., a pioneer in molecular profiling for.